Video

Susan G. Komen Greater New York City 4th Annual Patient Navigation Town Hall Livestream

Author(s):

CURE staff
Conference|Susan G. Komen Greater New York City Annual Patient Navigation Town Hall

In partnership with CURE®, Susan G. Komen Greater New York City hosts its 4th Annual Patient Navigation Town Hall "Empowering and Mobilizing Our Patient Navigation Workforce". Oncologists, community health workers and patient navigators will get together on June 23rd, via webinar, to discuss the impact of the COVID-19 pandemic on the cancer landscape and how professionals and patients can navigate the fallout moving forward.

In partnership with CURE®, Susan G. Komen® Greater New York City hosts its 4th Annual Patient Navigation Town Hall "Empowering and Mobilizing Our Patient Navigation Workforce". Leading health researchers, public policy experts, oncologists, community health workers and patient navigators will convene virtually on June 23rd, to discuss the impact of the COVID-19 pandemic on the cancer landscape; how healthcare professionals and patients are navigating the path forward; dealing with compassion fatigue and important workforce development "next steps" tailored to strengthen this important workforce.

For an overview of the entire program, go here!

Related Videos
Image of Doctor with blonde hair.
Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer.
Primary urothelial cancer has variable histologies, making its treatment complex, leading to varied outcomes with high rates of recurrence in patients.
Dr. Neeraj Agarwal is a medical oncologist, a professor of medicine and the Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah, as well as director of the Genitourinary Oncology Program and the Center of Investigational Therapeutics at the Huntsman Cancer Institute in Salt Lake City.
Image of Dr. Goy.
Image of bald man.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Image of Dr. Scott Kopetz
Image of Dr. Susumu Hijoka
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Related Content
Illustration of bladder.
February 21st 2025

Neoadjuvant Chemotherapy Plus Chemoradiation Safe, Effective in Bladder Cancer

Roman Fabbricatore
For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was effective in the long term.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Illustration of bladder cancer.
February 20th 2025

Bavencio and BSC Extends Survival in Bladder Cancer, Regardless of Diabetes Status

Jax DiEugenio
Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes mellitus status.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
An expert discusses the FDA approval of Enhertu in unresectable or metastatic HR+, HER2-low or -ultralow breast cancer: © stock.adobe.com
February 19th 2025

Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Cancer

Ryan Scott
Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer.
In patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses. © stock.adobe.com.
February 18th 2025

UGN-102 Shows Complete Response Rates in Low-Grade Bladder Cancer

Ashling Wahner
Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the phase 3 ENVISION and ATLAS studies.